Adult GlioblastomaPhase 1NCT04573140Papers
Autologous total tumor mRNA
RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
Sitagliptin in Recurrent/Progressive Grade 4 Glioma
What the film says
This trial is for grade 4 glioma, a brain tumor, that has returned or progressed after first line therapy, in adults.
The idea: use sitagliptin to inhibit myeloid derived suppressor cells, together with the standard of care drug bevacizumab. Doses are adjusted to find the maximal tolerated dose. The goal is proof of concept that suppressing these cells is safe and feasible.
This phase 1 trial plans 45 patients. At the University of Iowa in Iowa City, Kailin Yang leads it.
Public record; not medical advice.
Sources behind this film
Grade 4 glioma that returned or progressed after first line therapy, adults; Sitagliptin used to inhibit myeloid derived suppressor cells, together with standard of care bevacizumab; Doses adjusted to find the maximal tolerated dose; Proof of concept that suppressing these cells is safe and feasible (+2 more lines)
The drug
Sitagliptin, PO dose to be determined by Phase I dose de-escalation, cycle length 28 days. Treatment until progression.
Bevacizumab, IV, 10 mg/kg days 1 and 15 every 28 days, until progression.
In this Phase I trial, it is proposed that sitagliptin will be used to inhibit Myeloid Derived Suppressor Cells (MDSCs) in recurrent Glioblastoma (GBM). As this trial designed is for patients with recurrent GBM, patients will receive standard of care, bevacizumab, in addition to sitagliptin. The goal of this trial is to provide the proof of concept that suppressing MDSCs via sitagliptin is safe and feasible in patients with recurrent GBMs.
The study
Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of sitagliptin is appropriate to give when combined with bevacizumab.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.